In this article, we will examine the Best Emerging Technology Stocks to Buy Right Now.
While the telephone brought comfort, smartphones changed lives. While factories powered economies, artificial intelligence began rewriting them. Every generation experiences a turning point where technology doesn’t just improve how we live, but also reshapes the foundation of society. Today, we are at such a point.
Emerging technologies, including biotechnology, artificial intelligence, quantum computing, and autonomous systems, are redefining industries at a speed that rivals the Industrial Revolution. These are not incremental improvements, but they are disruptive forces with the potential to unlock new markets worth trillions of dollars. The pace of innovation is accelerating, and its impact reaches far beyond traditional technology companies.
This shift has been visible in financial markets over the last few years. The S&P 500 has been trending higher, with the Nasdaq leading the way as investors increased exposure to technology stocks. Recent gains have been concentrated in companies driving advances in areas like AI, cloud, and biotech, showing that emerging technologies are moving from the edges of the market to its center.
READ ALSO: Best Stocks For Day Trading: 12 Stock Picks and 15 Best Multibagger Stocks to Invest in Right Now.
Market leaders are echoing this sentiment. Kevin Mahn, president and CIO of Hennion & Walsh Asset Management, told CNBC on September 10 that the AI revolution is “alive and well.” He argued that Oracle’s recent results reinforce the momentum behind the AI boom, rather than being a one-off event.
Mahn pointed out that, just as Nvidia’s data center business has surged, Oracle’s cloud division is experiencing rapid growth, indicating that the investment opportunity in AI extends well beyond applications into the infrastructure that powers it.
In its June release, the World Economic Forum’s Top 10 Emerging Technologies of 2025 report underscored how quickly innovation is branching into new fields. Among the advances are structural battery composites that reduce weight while storing energy, biochemical sensors capable of continuous health or environmental monitoring, and watermarking tools designed to authenticate AI-generated content.
Together, as the forum believes, they reflect a future where technology is judged not only by efficiency but also by resilience, sustainability, and trust. While many of these remain in the early stages, they highlight the trajectory of innovation that public and private companies are beginning to commercialize.
Given this backdrop, let’s turn to our selection of the 11 best emerging technology stocks to buy right now.
Copyright: bugphai / 123RF Stock Photo
Our Methodology
To compile our list of best emerging technology stocks to buy, we screened U.S.-listed companies leading in innovative and disruptive technologies through vetting ETFs, industry reports, and online portals. We set a minimum market capitalization threshold of $300 million and required at least 20% potential upside to ensure meaningful growth prospects. From this universe, we selected 11 stocks with the strongest growth prospects (highest upside) and ranked them in ascending order based on their upside potential. We also included data on hedge fund holdings in these companies based on Insider Monkey’s database, as of Q2 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Note: All pricing data is as of market close on September 12, 2025.
11 Best Emerging Technology Stocks to Buy Right Now
11. CRISPR Therapeutics AG (NASDAQ:CRSP)
Focus Area: Gene editing through CRISPR/Cas9
Market Cap: $5.1 Billion
Potential Upside: 39%
Number of Hedge Fund Holders: 26
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on CRISPR Therapeutics AG (NASDAQ:CRSP) with an unchanged price target of $78.
The rating comes as the company continues to advance its CRISPR/Cas9 gene-editing platform, a breakthrough technology for gene editing that enables precise changes to DNA sequences and directly corrects faulty genes. With a pipeline that spans treatments for blood disorders, cancer, and rare genetic diseases, CRISPR Therapeutics AG (NASDAQ:CRSP) is positioning itself at the forefront of one of the most disruptive innovations in biotechnology.
While still in the early stages of commercialization, the technology’s potential to reshape the treatment landscape is becoming increasingly clear.
That view had also been echoed earlier by H.C. Wainwright analyst Mitchell Kapoor. On August 7, the analyst reiterated a Buy rating and lifted his price target to $80 from $65, citing a 114% quarter-over-quarter increase in CASGEVY sales during Q2 2025.
He pointed to accelerating patient adoption, bolstered by the expansion of 75 authorized treatment centers, as well as CRISPR Therapeutics AG’s (NASDAQ:CRSP) strong cash position that extends its operating runway into 2027.
Kapoor also added projections for CTX310 to his model, estimating peak revenue potential of $4 billion, which further strengthens the long-term growth story.
We can safely say that the combination of analyst conviction, rising sales momentum, and a robust pipeline suggests that CRISPR is beginning to shift from a promise to delivery, offering investors exposure to one of the most compelling stories in emerging biotechnology.
CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene-editing company that is developing transformative therapies using its proprietary CRISPR/Cas9 platform. Its pipeline spans treatments for hemoglobinopathies, oncology, regenerative medicine, and rare genetic diseases.
10. AST SpaceMobile Inc. (NASDAQ:ASTS)
Focus Area: Space-based cellular broadband
Market Cap: $13.9 Billion
Potential Upside: 45%
Number of Hedge Fund Holders: 30
AST SpaceMobile Inc. (NASDAQ:ASTS) is one of the best emerging technology stocks to buy right now. The company is positioning itself as a pioneer in next-generation telecom, developing the first satellite-based broadband network designed to connect directly to standard mobile phones.
By combining satellite technology with existing cellular infrastructure, the company aims to address one of the industry’s most significant gaps in providing affordable, seamless coverage in remote and underserved regions.
The company has tremendous opportunities. AST SpaceMobile Inc. (NASDAQ:ASTS) estimates the 10-year demand for satellite direct-to-device communications at roughly $100 billion, within a global mobile wireless services market exceeding $1 trillion.
With its low-earth orbit (LEO) BlueBird satellite constellation, the company aims to turn that potential into scale, moving closer to commercial rollout.
On September 4, the company disclosed that its first Block 2 BlueBird satellite, BlueBird 6, is now fully assembled and undergoing final tests before shipment. The company also confirmed that 20 satellites have received approval from the Federal Communications Commission for launch, underscoring steady operational progress.
Days later, Scott Searle, an analyst at Roth MKM, reiterated a Buy rating with a $56 price target. Searle’s September 8 note reflects his continued confidence in AST SpaceMobile Inc.’s (NASDAQ:ASTS) ability to deliver on its vision of space-based cellular connectivity.
However, unlike Searle, not all views remain bullish. On September 9, UBS analyst Chris Schoell downgraded the stock to Hold and cut the price target to $43 from $62. Schoell flagged heightened competition following Starlink’s acquisition of Echostar’s S-Band spectrum, which bolsters Starlink’s standing in the space-to-cellular market.
He cautioned that the stronger rival presence raises execution risks for AST SpaceMobile Inc. (NASDAQ:ASTS) and could push carriers to diversify partnerships, thereby challenging AST’s ability to capture market share.
9. Ehang Holdings Ltd. (NASDAQ:EH)
Focus Area: Autonomous aerial vehicles (AAVs)
Market Cap: $1.2 Billion
Potential Upside: 45%
Number of Hedge Fund Holders: 12
Ehang Holdings Ltd. (NASDAQ:EH) is one of the best emerging technology stocks to buy right now. EHang is emerging as a frontrunner in passenger-grade autonomous aerial vehicles. Its flagship EH216 is among the first certified autonomous eVTOL aircraft, designed for urban transport, logistics, and emergency services.
Ehang Holdings Ltd. (NASDAQ:EH) is pursuing an autonomy-first approach, rather than relying on piloted models, which differentiates it from its peers and positions its technology for broader scalability.
On August 26, Bank of America Securities analyst Fiona Liang reiterated a Buy rating on the stock, highlighting the company’s position in the eVTOL industry. Although Q2 2025 results reflected weaker-than-expected deliveries, revenue increased sharply from the previous year, and margins showed a slight improvement.
Management also lowered its full-year revenue forecast, prioritizing safe operations and a disciplined path toward commercialization.
The analyst also highlighted that the company continues to expand through new orders and partnerships, including efforts in China and Thailand. There was recently a collaboration with the Hefei government to establish a production hub for next-generation aircraft, which adds to its progress.
With China expected to be a key driver of eVTOL adoption, these steps support Ehang Holdings Ltd.’s (NASDAQ:EH) growth outlook as well as Liang’s bullish view.
8. Archer Aviation Inc. (NYSE:ACHR)
Focus Area: Electric vertical take-off and landing (eVTOL) aircraft
Market Cap: $5.6 Billion
Potential Upside: 49%
Number of Hedge Fund Holders: 35
Archer Aviation Inc. (NYSE:ACHR) is one of the best emerging technology stocks to buy right now. The company is another player on this list that is involved in the development of electric vertical takeoff and landing (eVTOL) aircraft designed for urban air mobility, with its Midnight aircraft targeting commercial operations in the near future.
The eVTOL sector is in its early stages, with no mass adoption yet. Six of Archer Aviation Inc.’s (NYSE:ACHR) flagship Midnight aircraft are in production, with three currently in final assembly. Archer is leading the race with its advances toward FAA certification and strong partnerships with automakers and airlines.
In line with its expansion efforts, on September 12, Archer Aviation Inc. (NYSE:ACHR) announced its intent to participate in the White House’s newly established eVTOL Integration Pilot Program (eIPP), a federal initiative aimed at accelerating real-world electric air taxi operations in the U.S. The company is working with United Airlines and interested cities to design trial operations for its Midnight aircraft.
The eIPP, created under an Executive Order signed in June, authorizes the Department of Transportation and the Federal Aviation Administration to establish pre-certification operating environments for eVTOLs. Archer Aviation Inc. (NYSE:ACHR) believes that it can use this opportunity to validate the superiority of its technology to foster public and regulatory acceptance.
Management described the development as a milestone for the industry. Adam Goldstein, Archer’s Founder and CEO, stated:
“This is a landmark moment for our industry and our country. We have an Administration that is prioritizing the integration of eVTOL operations in U.S. cities ahead of full certification in a pragmatic way. We’ll demonstrate that air taxis can operate safely and quietly. These early flights will help cement American leadership in advanced aviation and set the stage for scaled commercial operations in the U.S. and beyond.”
Earlier, on August 12, H.C. Wainwright analyst Amit Dayal reiterated a Buy rating on the stock, citing steady progress toward the company’s 2026 commercialization target. Despite the absence of revenue in the recent quarter, Dayal noted that Archer Aviation Inc. (NYSE:ACHR) had achieved key milestones in its manufacturing and certification efforts, both essential steps for eventual deliveries to its Launch Edition customers.
When combined, the company’s regulatory advances and analyst confidence highlight its growing potential in next-generation air mobility.
Archer Aviation Inc. (NYSE:ACHR) is a U.S.-based aerospace company developing electric vertical take-off and landing (eVTOL) aircraft for urban air mobility.
7. Aeva Technologies Inc. (NASDAQ:AEVA)
Focus Area: 4D LiDAR-on-chip sensors
Market Cap: $903 Million
Potential Upside: 56%
Number of Hedge Fund Holders: 19
Aeva Technologies Inc. (NASDAQ:AEVA) is one of the best emerging technology stocks to buy right now. The company develops 4D LiDAR sensors based on frequency-modulated continuous-wave (FMCW) technology. This technology enables the simultaneous measurement of distance and velocity, which is critical for autonomous vehicles and robotics.
Traditional LiDAR solutions are still too costly and challenging to produce on a large scale. This leaves an opportunity for new and more affordable solutions to enter the market.
Aeva Technologies Inc. (NASDAQ:AEVA) has created an innovative “LiDAR-on-chip” that is smaller, more affordable, and more powerful than traditional sensors. The technology could play a pivotal role in enabling autonomous machines and vehicles, opening an addressable market of more than $80 billion across transportation, defense, robotics, and consumer applications.
The stock has delivered outsized gains of more than 230% year-to-date but has since corrected nearly 60% to $16 from its June peak of $37, levels last seen in late 2021. While most analysts continue to rate the stock as a Buy, some cautionary voices remain, such as Morgan Stanley’s Joseph Moore, a long-time skeptic.
On August 18, Moore reiterated a Hold rating on Aeva Technologies Inc. (NASDAQ:AEVA) with a $19 price target. In his note, he acknowledged that the company has made strong progress in bringing its technology closer to commercialization. Its investment in R&D has produced a competitive platform that combines software, system-on-chip, and LiDAR technology, reinforcing the company’s technical edge in FMCW.
Still, Moore pointed to competitive risks, especially from low-cost Chinese players that could pressure pricing in what remains a deflationary market. He also noted that while Aeva Technologies Inc.’s (NASDAQ:AEVA) automotive engagements are advancing, broader adoption across other sectors is still in its early stages.
Aeva Technologies Inc. (NASDAQ:AEVA) designs and manufactures advanced LiDAR sensing systems and perception software, using Frequency Modulated Continuous Wave (FMCW) sensing.
6. Twist Bioscience Corp. (NASDAQ:TWST)
Focus Area: Synthetic DNA manufacturing
Market Cap: $1.5 Billion
Potential Upside: 78%
Number of Hedge Fund Holders: 23
Twist Bioscience Corp. (NASDAQ:TWST) is one of the best emerging technology stocks to buy right now. The company manufactures synthetic DNA using a silicon-based synthesis platform, enabling scalable production at a level of accuracy and affordability that traditional methods struggle to match.
The platform has applications across drug discovery, diagnostics, agriculture, and even data storage. While synthetic biology is still in its early stages, Twist is emerging as a front-runner in shaping its commercial potential.
On September 12, TD Cowen analyst Brendan Smith reaffirmed a Buy rating on Twist Bioscience Corp. (NASDAQ:TWST) with a $36 price target. His note followed the company’s September 9 presentation at the Baird Global Healthcare Conference 2025, where management outlined progress in profitability, operating efficiency, and strategic priorities.
The company reported that its gross margins now exceed 50%, which reflects both scale and disciplined execution. Management reiterated its goal of reaching adjusted EBITDA breakeven by fiscal 2026, adding that every incremental dollar of revenue contributes roughly $0.75 to $0.80 to gross margin.
For the coming years, management highlighted several levers for growth, including expansion of the MRD opportunity, customer migration from microarrays to Twist Bioscience Corp.’s (NASDAQ:TWST) sequencing solutions, and further integration between Synbio and Biopharma. At the same time, they noted that challenges persist, including a difficult funding environment and the need to balance cost discipline with continued innovation.
Twist Bioscience Corp. (NASDAQ:TWST) is a synthetic biology company that manufactures DNA using a proprietary silicon-based platform. Its method allows DNA to be produced directly on a chip, making the process faster, more efficient, and cost-effective compared to traditional techniques.
5. Redwire Corp. (NYSE:RDW)
Focus Area: Space infrastructure and in-orbit manufacturing
Market Cap: $1.3 Billion
Potential Upside: 101%
Number of Hedge Fund Holders: 22
Redwire Corp. (NYSE:RDW) is one of the best emerging technology stocks to buy right now. The company develops space infrastructure technologies, including deployable structures, satellite power systems, and in-orbit manufacturing. The company has also advanced research in 3D bioprinting in microgravity, highlighting its role in the growing space economy.
Despite these strengths, Redwire Corp. (NYSE:RDW) shares have fallen 47% year-to-date. Analysts see potential for recovery and the broader consensus suggests over 100% potential upside for the stock. However, questions surrounding growth visibility and shareholder actions have added caution.
On August 18, Bank of America analyst Ronald Epstein started coverage of Redwire Corp. (NYSE:RDW) with an Underperform rating and a $10 price target. He cautioned that the company relies heavily on government space contracts, which limit its growth potential. Epstein also flagged earnings volatility, dependence on acquisitions, and its concentrated ownership as added risks compared to other space and defense tech peers.
Among the key concerns for Epstein is Redwire’s ownership structure. Following the Edge Autonomy deal and a capital raise, two private equity firms now collectively hold approximately 87% of the company’s shares. These investors have also signaled plans to sell a large chunk of their stake, reportedly over 75%, in the future. According to Epstein, such heavy insider selling could weigh on the stock price and make it harder for Redwire Corp. (NYSE:RDW) to raise new funds, adding further uncertainty for investors.
Redwire Corp. (NYSE:RDW) supplies space infrastructure and high-reliability components for the emerging space economy. The company holds key intellectual property in areas such as solar power systems and in-space 3D printing and manufacturing.
4. Beam Therapeutics Inc. (NASDAQ:BEAM)
Focus Area: Gene editing via base editing
Market Cap: $2.1 Billion
Potential Upside: 106%
Number of Hedge Fund Holders: 31
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best emerging technology stocks to buy right now. The company develops precision genetic medicines using base editing, a next-generation approach that makes single-letter changes in DNA without cutting the double helix.
This innovation reduces risks associated with traditional gene editing and offers higher accuracy. Beam’s platform could become the standard for safe and precise genetic corrections, placing it firmly among emerging biotech leaders.
On September 15, Patrick Trucchio from H.C. Wainwright maintained his Buy rating on Beam Therapeutics Inc. (NASDAQ:BEAM), keeping his price target of $80 unchanged. The analyst based his positive stance on the company’s steady progress across its base editing pipeline, both ex vivo and in vivo.
The analyst highlighted several products in the pipeline to make his case. He said Beam Therapeutics Inc.’s (NASDAQ:BEAM) lead program, BEAM-101, is advancing as a registrational candidate for sickle cell disease and could move toward a BLA filing in the near term. Alongside this, BEAM-302 is in dose expansion studies for alpha-1 antitrypsin deficiency and has been drawing strong investor interest. Early data suggest it could be a best-in-class therapy, showing meaningful biochemical improvements, with ongoing work focused on dose optimization.
Trucchio noted that while BEAM-302 has emerged as a potential star program, the sickle cell franchise anchored by BEAM-101 remains central to Beam’s strategy.
Beam Therapeutics Inc. (NASDAQ: BEAM) is a biotechnology company that develops precision genetic medicines using base editing technologies for the treatment of various diseases.
3. Aurora Innovation Inc. (NASDAQ:AUR)
Focus Area: Autonomous driving technology for freight
Market Cap: $10.5 Billion
Potential Upside: 112%
Number of Hedge Fund Holders: 41
Aurora Innovation Inc. (NASDAQ:AUR) is one of the best emerging technology stocks to buy right now. The company develops self-driving systems, with a focus on long-haul trucking through its Aurora Driver platform. Autonomous trucking promises cost savings, increased safety, and better efficiency, but its commercialization is still in its early stages.
Aurora’s partnerships with logistics companies and OEMs give it an edge in a field that could transform freight transport over the next decade.
On September 15, Cantor Fitzgerald analyst Andres Sheppard reiterated an Overweight rating on Aurora Innovation Inc. (NASDAQ:AUR) with a $12 price target. Sheppard pointed to multiple upcoming catalysts, including an expected ramp in driverless commercial loads in the second half of 2025 and expanded testing on new freight routes such as Fort Worth-El Paso and Phoenix.
The analyst also noted Aurora’s progress in preparing its system for tougher driving environments, such as rain and heavy winds, an important step for scaling adoption.
In addition, Sheppard pointed to Aurora Innovation Inc.’s (NASDAQ:AUR) first-mover position, supportive regulatory environment, and asset-light, high-margin model as key factors that can help the company scale efficiently. Its deep partnerships with industry leaders further reinforce its path toward commercialization.
Aurora Innovation Inc. (NASDAQ:AUR) is a self-driving technology company specializing in autonomous freight and logistics. Its flagship platform, the Aurora Driver, powers driverless trucks already operating on public roads.
2. Butterfly Network Inc. (NYSE:BFLY)
Focus Area: Ultrasound-on-a-chip imaging
Market Cap: $395 Million
Potential Upside: 123%
Number of Hedge Fund Holders: 22
Butterfly Network Inc. (NYSE:BFLY) is one of the best emerging technology stocks to buy right now. The company has created a handheld ultrasound device that connects to smartphones, powered by its semiconductor-based, patented ultrasound-on-a-chip technology.
This innovation makes medical imaging cheaper, easier to use, and accessible outside of big hospitals. With mass adoption possible in clinics and developing countries, Butterfly Network Inc. (NYSE:BFLY) could disrupt the way healthcare diagnostics are performed.
On September 8, TD Cowen analyst Josh Jennings reaffirmed a Buy rating on Butterfly Network Inc. (NYSE:BFLY) with a $3.50 price target, following the release of results from the POCUS-CARE trial.
The study showed that Butterfly’s iQ3 handheld ultrasound device can materially reduce both lower hospital costs and shorten patient stays. Jennings believes that these outcomes support iQ3’s effectiveness and case for its wider adoption.
Jennings also commented on the stock’s nearly 30% decline since late July, attributing the weakness to near-term headwinds flagged on the Q2 2025 earnings call. He described these pressures as temporary and cyclical in nature, rather than lasting challenges, and argued that the pullback appears excessive when considered in light of Butterfly’s long-term fundamentals.
With new clinical evidence and a unique technology, Jennings maintains that Butterfly Network Inc. (NYSE:BFLY) is well-positioned to carry out its rollout strategy, justifying the Buy rating.
Butterfly Network Inc. (NYSE:BFLY) is a healthcare company that provides medical imaging solutions using its proprietary Ultrasound-on-Chip semiconductor technology and ultrasound software.
1. Sana Biotechnology Inc. (NASDAQ:SANA)
Focus Area: Cell and gene therapy engineering
Market Cap: $828 Million
Potential Upside: 180%
Number of Hedge Fund Holders: 16
Sana Biotechnology Inc. (NASDAQ:SANA) is one of the best emerging technology stocks to buy right now. The company develops next-generation cell and gene therapies, including ex vivo engineered cells and in vivo delivery technologies.
Its focus is on creating medicines that can repair or control genes and replace damaged cells. Still in early clinical stages, Sana Biotechnology Inc. (NASDAQ:SANA) represents the frontier of regenerative medicine, with transformative potential but significant development risk.
Following the company’s second-quarter 2025 results on August 11, H.C. Wainwright analyst Emily Bodnar reaffirmed a Buy rating on Sana Biotechnology (NASDAQ:SANA) with a price target of $11.
Bodnar pointed to encouraging progress in the company’s UP421 program, which demonstrated islet cell survival and function in type 1 diabetes patients without immunosuppression, an important proof point for Sana’s hypoimmune (HIP) platform.
The analyst also highlighted that, in parallel, the company is advancing SC451, a one-time iPSC-derived HIP-modified islet cell therapy, supported by positive feedback from a pre-IND FDA INTERACT meeting that lays the groundwork for an IND filing in 2026.
Financially, Sana’s balance sheet is strong (cash position of around $177 million) and provides a good runway to pursue these development milestones. Bodnar emphasized that the scalability and immunosuppression-free profile of SC451 position it for a significant market opportunity.
Sana Biotechnology (NASDAQ:SANA) is a clinical-stage biotechnology company focused on creating and delivering engineered cells as a form of medicine.
While we acknowledge the potential of SANA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SANA and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: Best Stocks For Day Trading: 12 Stock Picks and 15 Best Multibagger Stocks to Invest in Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
